SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

Search

Innate Pharma SA

Fechado

1.532 1.32

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.486

Máximo

1.572

Indicadores-chave

By Trading Economics

Rendimento

57K

-25M

Vendas

-8M

4.3M

Margem de lucro

-570.732

Funcionários

181

EBITDA

2.5M

-23M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+105.13% upside

Dividendos

By Dow Jones

Próximos Ganhos

17 de set. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

117K

153M

Abertura anterior

0.21

Fecho anterior

1.532

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Innate Pharma SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de jun. de 2025, 23:49 UTC

Ganhos

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 de jun. de 2025, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 de jun. de 2025, 21:30 UTC

Ganhos

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 de jun. de 2025, 21:07 UTC

Ganhos

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 de jun. de 2025, 23:49 UTC

Conversa de Mercado

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 de jun. de 2025, 23:39 UTC

Conversa de Mercado

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 de jun. de 2025, 23:34 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 de jun. de 2025, 23:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 de jun. de 2025, 23:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 de jun. de 2025, 23:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 de jun. de 2025, 23:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 de jun. de 2025, 23:31 UTC

Aquisições, Fusões, Aquisições de Empresas

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 de jun. de 2025, 23:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 de jun. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 de jun. de 2025, 23:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 de jun. de 2025, 22:06 UTC

Ganhos

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 de jun. de 2025, 21:15 UTC

Ganhos

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 de jun. de 2025, 21:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 de jun. de 2025, 21:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 de jun. de 2025, 21:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 de jun. de 2025, 21:07 UTC

Ganhos

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 de jun. de 2025, 21:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 de jun. de 2025, 21:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 de jun. de 2025, 21:06 UTC

Conversa de Mercado

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 de jun. de 2025, 21:05 UTC

Aquisições, Fusões, Aquisições de Empresas

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 de jun. de 2025, 21:05 UTC

Aquisições, Fusões, Aquisições de Empresas

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 de jun. de 2025, 20:52 UTC

Ganhos

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 de jun. de 2025, 20:51 UTC

Ganhos

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

Comparação entre Pares

Variação de preço

Innate Pharma SA Previsão

Preço-alvo

By TipRanks

105.13% parte superior

Previsão para 12 meses

Média 3.098 EUR  105.13%

Máximo 3.1 EUR

Mínimo 3.1 EUR

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Innate Pharma SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

0

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.91 / 2.1Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.